Houston, TX 的 脂肪性肝病 臨床試驗
13 項針對 脂肪性肝病 的研究正在 Houston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
招募中3 期
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
招募中3 期
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 89bio Clinical Study Site, Houston
- 還有 1 項
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中3 期
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 距離 7 英里
- GSK Investigational Site, Humble · 距離 17 英里
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中3 期
- GSK Investigational Site, Bellaire · 距離 7 英里
- GSK Investigational Site, Humble · 距離 17 英里
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
招募中2 期
- Pioneer Research Solutions, Inc., Houston
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
招募中3 期
- HRI- Medical Center, Houston
- Care Access - Houston, Houston
- Houston Research Institute, Houston
- 還有 3 項
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
招募中3 期
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- Akero Clinical Study Site, Houston
- 還有 3 項
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
招募中2 期
- Houston Research Institute - Medical Center, Houston
- Houston Research Institute, Houston
- Bellaire Clinical Research, Bellaire · 距離 7 英里
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
招募中3 期
- GSK Investigational Site, Houston
- GSK Investigational Site, Bellaire · 距離 7 英里
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
招募中2 期
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
- GSK Investigational Site, Houston
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
招募中1/2 期歡迎健康志工
- Pioneer Research Solutions, Houston
NAFLD Clinical Care Pathway
招募中歡迎健康志工
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
招募中觀察性研究
- First Surgical Hospital, Bellaire · 距離 7 英里
其他城市的 脂肪性肝病 試驗
- San Antonio, TX17 項研究
- Miami, FL16 項研究
- New York City, NY16 項研究
- San Diego, CA14 項研究
- Austin, TX13 項研究
- Richmond, VA12 項研究
- Tucson, AZ10 項研究
- Chandler, AZ10 項研究
- Orlando, FL9 項研究
- St. Louis, MO9 項研究
- Dallas, TX9 項研究
- Hialeah, FL9 項研究
Houston 的其他研究
- 非小細胞肺癌145 項研究
- 乳癌126 項研究
- 癌症（所有類型）121 項研究
- 轉移性癌症104 項研究
- 大腸直腸癌102 項研究
- 卵巢癌89 項研究
- 急性髓系白血病85 項研究
- 肺癌78 項研究
- 前列腺癌76 項研究
- 子宮內膜癌68 項研究
- 胰臟癌61 項研究
- 黑色素瘤59 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。